Major Depressive Disorder
Conditions
Keywords
electroconvulsive therapy, memantine, cognitive function, memory
Brief summary
The purpose of this study is to determine whether memantine will enhance the therapeutic of effect on depression and prevent memory and other cognitive problems caused by ECT.
Detailed description
Patients will be assigned randomly either to a treatment group or a placebo groups. All patients in both groups will be receiving standard ECT. The treatment group will receive memantine. All patients will be given a battery of cognitive tests and test of depression before ECT treatments start, after the 6th ECT treatment and after the completions of ECT. An analysis will be performed to see if memantine causes any impact on the response to ECT and prevents memory and cognitive impairment.
Interventions
DRUGmemantine
patient will receive 5mg daily for 7day then 10 mgm daily
DRUGPlacebo
will give placebo that looks like memantine
Sponsors
Jerrry L Lewis
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Meets criteria for Major Depressive disorder
Exclusion criteria
* Neurological disease * Mental retardation * Seizure disorder
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of whether Memantine protects memory and cognitive impairment caused by ECT. | 6 to 8 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Whether memantine will improve response of Depression to Electroconvulsive therapy. | 6-8 weeks |
Countries
United States
Outcome results
None listed